Semaphorin 6A (SEMA6A) inhibits colorectal cancer progression and boosts anti-PD-1 immunity

Colorectal cancer (CRC) remains a significant global health challenge, with current therapies often limited by tumor progression and immune evasion. Semaphorins (SEMAs) are a diverse family of proteins known to influence tumor development and immune responses, yet their specific roles in CRC are largely underexplored. A critical gap exists in understanding how SEMAs might modulate the tumor microenvironment and enhance anti-tumor immunity, particularly in the context of immunotherapy resistance. This study investigates SEMA6A as a potential dual therapeutic target to address both cancer progression and immune evasion.

Researchers investigated SEMA6A's role in CRC using both in vitro cell culture assays and in vivo experiments, likely in a rodent model, though specific species and N are not detailed in the abstract. They assessed SEMA6A expression in CRC tissues and correlated it with tumor aggressiveness and patient prognosis. Functional assays evaluated the anti-tumor effects of SEMA6A overexpression. Integrated RNA-seq and proteomic analyses identified downstream effectors. Mechanistic studies, including molecular docking, co-immunoprecipitation, and cycloheximide chase assays, elucidated the ISG15/TGFβ pathway. In vitro co-culture assays and in vivo studies examined CD8+ T cell cytotoxicity and the potentiation of anti-PD-1 immunotherapy.